RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer
Flavia Jacobs(Fondazione IRCCS Istituto Nazionale dei Tumori), Alberto Zambelli, C. Benvenuti, Salvatore D’Amico, Rita De Sanctis(Humanitas University), R. Buonaiuto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Federica Martorana(University of Catania), Grazia Arpino(University of Naples Federico II), M. Gaudio(Humanitas University), Paolo Vigneri(Humanitas University), Carlo Tondini(Ospedale Papa Giovanni XXIII), Emanuela Ferraro(University of Milan), Mario Giuliano(Regione Campania), Rossana Di Rienzo(University of Naples Federico II), Giuseppe Saltalamacchia, Evandro de Azambuja(Université Libre de Bruxelles), Elisa Agostinetto(Université Libre de Bruxelles), Riccardo Gerosa(Humanitas University), Matteo Giovanni Della Porta(Humanitas University), Elena Zazzetti(IRCCS Humanitas Research Hospital), Alessandra Chirco(Ospedale Papa Giovanni XXIII), Armando Santoro(IRCCS Humanitas Research Hospital), Monica Fornier(Cornell University)
Cited by 0
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
|British Journal of Cancer|2007|957